Loading
A phase 1/2 trial of STX-721/PFL-721 (Escalated) in non-small-cell lung cancer, run by Pierre Fabre Medicament, now recruiting.
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations is a phase 1/2 interventional study registered as NCT06043817 by Pierre Fabre Medicament, with 345 participants planned, started 2023-09-26 and due to reach its primary completion in 2029-12-01. Interventions recorded: STX-721/PFL-721 (Escalated), STX-721/PFL-721 (3 dose levels) and STX-721/PFL-721 (RP2D).
Shares Pierre Fabre, EGFR-mutated non-small-cell lung cancer, EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares HER2-mutant non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer, EGFR, HER2 and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares HER2-mutant non-small-cell lung cancer, HER2, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, HER2, Non-small-cell lung cancer and the tag pipeline.